Original Article
OPEN ACCESS: Impact of Policy Change on Access to Medication for Opioid Use Disorder in Primary Care
Abstract
Objectives: The opioid overdose epidemic is escalating. Increasing access to medications for opioid use disorder in primary care is crucial. The impact of the US Department of Health and Human Services’ policy change removing the buprenorphine waiver training requirement on primary care buprenorphine prescribing remains unclear. We aimed to investigate the impact of the policy change on primary care providers’ likelihood of applying for a waiver and the current attitudes, practices, and barriers to buprenorphine prescribing in primary care.Methods: We used a cross-sectional survey with embedded educational resources disseminated to primary care providers in a southern US academic health system. We used descriptive statistics to aggregate survey data, logistic regression models to evaluate whether buprenorphine interest and familiarity correlate with clinical characteristics, and a χ2 test to evaluate the effect of the educational intervention on screening.
Results: Of the 54 respondents, 70.4% reported seeing patients with opioid use disorder, but only 11.1% had a waiver to prescribe buprenorphine. Few nonwaivered providers were interested in prescribing, but perceiving buprenorphine to be beneficial to the patient population was associated with interest (adjusted odds ratio 34.7, P < 0.001). Two-thirds of nonwaivered respondents reported the policy change having no impact on their decision to obtain a waiver; however, among interested providers, it increased their likelihood of obtaining a waiver. Barriers to buprenorphine prescribing included lack of clinical experience, clinical capacity, and referral resources. Screening for opioid use disorder did not increase significantly after the survey.
Conclusions: Although most primary care providers reported seeing patients with opioid use disorder, interest in prescribing buprenorphine was low and structural barriers remained the dominant obstacles. Providers with a preexisting interest in buprenorphine prescribing reported that removing the training requirement was helpful.
Full Article
Having trouble viewing the article content below? Click here to open it directly.
Images
References
1. Centers for Disease Control and Prevention. U.S. overdose deaths in 2021 increased half as much as in 2020—but are still up 15%. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm. Updated May 11, 2022. Accessed June 26, 2022.
2. Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med 2018;169:137–145.
3. Morgan JR, Schackman BR, Leff JA, et al. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat 2018;85:90–96.
4. Haffajee RL, Bohnert ASB, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med 2018; 54(6 suppl 3):S230–S242.
5. Grimm CA. Geographic disparities affect access to buprenorphine services for opioid use disorder. https://oig.hhs.gov/oei/reports/oei-12-17-00240.asp. Published January 29, 2020. Accessed January 20, 2023.
6. Willis J, Antono B, Bazemore A, et al. The state of primary care in the United States: a chartbook of facts and statistics. https://www.graham-center.org/content/dam/rgc/documents/publications-reports/reports/PrimaryCareChartbook2021.pdf. Published February 2021. Accessed January 20, 2023.
7. Wang PS, Lane M, Olfson M, et al. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:629–640.
8. Korthuis PT, McCarty D, Weimer M, et al. Primary care-based models for the treatment of opioid use disorder: a scoping review. Ann Intern Med 2017; 166:268–278.
9. Korownyk C, Perry D, Ton J, et al. Opioid use disorder in primary care: PEER umbrella systematic review of systematic reviews. Can Fam Physician 2019; 65:e194–e206.
10. Gertner AK, Robertson AG, Powell BJ, et al. Primary care providers and specialists deliver comparable buprenorphine treatment quality. Health Aff (Millwood) 2020;39:1395–1404.
11. Wen H, Borders TF, Cummings JR. Trends in buprenorphine prescribing by physician specialty. Health Aff (Millwood) 2019;38:24–28.
12. Olfson M, Zhang V, Schoenbaum M, et al. Buprenorphine treatment by primary care providers, psychiatrists, addiction specialists, and others. Health Aff (Millwood) 2020;39:984–992.
13. Rosenblatt RA, Andrilla CH, Catlin M, et al. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med 2015;13:23–26. doi:10.1370/afm.1735.
14. Saloner B, Lin L, Simon K. Geographic location of buprenorphine-waivered physicians and integration with health systems. J Subst Abuse Treat. Aug 2020;115:108034. doi:10.1016/j.jsat.2020.108034.
15. US Department of Health and Human Services. Practice guidelines for the administration of buprenorphine for treating opioid use disorder. https://www.federalregister.gov/documents/2021/04/28/2021-08961/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder. Published April 28, 2021. Accessed June 26, 2022.
16. Drug Policy Alliance. Statement on HHS’ new guidelines removing barriers from medical practitioners to prescribe life-saving medication for opioid use disorder. https://drugpolicy.org/press-release/2021/04/statement-hhs-new-guidelines-removing-barriers-medical-practitioners. Published April 27, 2021. Accessed June 26, 2022.
17. Louie DL, Assefa MT, McGovern MP. Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review. BMC Fam Pract 2019; 20:157.
18. Cole ES, DiDomenico E, Green S, et al. The who, the what, and the how: a description of strategies and lessons learned to expand access to medications for opioid use disorder in rural America. Subst Abus 2021;42:123–129.
19. Foti K, Heyward J, Tajanlangit M, et al. Primary care physicians' preparedness to treat opioid use disorder in the United States: a cross-sectional survey. Drug Alcohol Depend 2021;225:108811.
20. McGinty EE, Stone EM, Kennedy-Hendricks A, et al. Medication for opioid use disorder: a national survey of primary care physicians. Ann Intern Med 2020;173:160–162.
21. DeFlavio JR, Rolin SA, Nordstrom BR, et al. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health 2015;15:3019.
22. Clark B, Kai M, Dix R, et al. Association of a multimodal educational intervention for primary Care physicians with prescriptions of buprenorphine for opioid use disorders. JAMA Netw Open 2019;2:e1913818.
23. Boggiano V, Gilmore Wilson C, Fagan EB, et al. The impact on future prescribing patterns of opioid use disorder (OUD) education and waiver provision during residency. J Am Board Fam Med 2020;33:998–1003.
24. Gregory HM, Hill VM, Parker RW. Implications of increased access to buprenorphine for medical providers in rural areas: a review of the literature and future directions. Cureus 2021;13:e19870.
25. US Department of Health and Human Services. HHS releases new buprenorphine practice guidelines, expanding access to treatment for opioid use disorder. https://www.samhsa.gov/newsroom/press-announcements/202104270930. Updated January 14, 2021. Accessed June 26, 2022.
26. Spetz J, Hailer L, Gay C, et al. Changes in US clinician waivers to prescribe buprenorphine management for opioid use disorder during the COVID-19 pandemic and after relaxation of training requirements. JAMA Network Open 2022;5:e225996.
27. Fiscella K, Wakeman SE, Beletsky L. Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver. JAMA Psychiatry 2019;76:229–230.
28. D’Onofrio G, Melnick ER, Hawk KF. Improve access to care for opioid use disorder: a call to eliminate the X-waiver requirement now. Ann Emerg Med 2021;78:220–222.
29. Removal of DATA Waiver (X-Waiver) Requirement. Substance Abuse and Mental Health Services Administration. 2023. Available at: https://www.samhsa.gov/medications-substance-use-disorders/removal-data-waiver-requirement. Accessed January 29, 2023.
30. Accreditation Council for Graduate Medical Education. ACGME program requirements for graduate medical education in internal medicine. https://www.acgme.org/globalassets/pfassets/programrequirements/140_internalmedicine_2022v3.pdf. Published February 7, 2022. Accessed June 26, 2022.
31. Anderson JB, Martin SA, Gadomski A, et al. Project ECHO and primary care buprenorphine treatment for opioid use disorder: implementation and clinical outcomes. Subst Abus 2022;43:222–230.
32. Brackett CD, Duncan M, Wagner JF, et al. Multidisciplinary treatment of opioid use disorder in primary care using the collaborative care model. Subst Abus 2022;43:240–244.
33. Reif S, Brolin MF, Stewart MT, et al. The Washington state hub and spoke model to increase access to medication treatment for opioid use disorders. J Subst Abuse Treat 2020;108:33–39.
34. Komaromy M, Duhigg D, Metcalf A, et al. Project ECHO (Extension for Community Healthcare Outcomes): a new model for educating primary care providers about treatment of substance use disorders. Subst Abus 2016;37:20–24.
35. Spelman JF, Edens EL, Maya S, et al. A facility-wide plan to increase access to medication for opioid use disorder in primary care and general mental health settings. Fed Pract 2021;38:460–464.
36. Weintraub E, Seneviratne C, Anane J, et al. Mobile telemedicine for buprenorphine treatment in rural populations with opioid use disorder. JAMA Netw Open 2021;4:e2118487.
37. Wu LT, John WS, Ghitza UE, et al. Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network. Addiction 2021;116:1805–1816.
38. Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med 2011;171:425–431.
39. Lanham HJ, Papac J, Olmos DI, et al. Survey of barriers and facilitators to prescribing buprenorphine and clinician perceptions on the Drug Addiction Treatment Act of 2000 waiver. JAMA Network Open 2022;5:e2212419.
